HUE066043T2 - A TR kináz beterociklusos inhibitorai - Google Patents

A TR kináz beterociklusos inhibitorai

Info

Publication number
HUE066043T2
HUE066043T2 HUE18831104A HUE18831104A HUE066043T2 HU E066043 T2 HUE066043 T2 HU E066043T2 HU E18831104 A HUE18831104 A HU E18831104A HU E18831104 A HUE18831104 A HU E18831104A HU E066043 T2 HUE066043 T2 HU E066043T2
Authority
HU
Hungary
Prior art keywords
atr kinase
heterocyclic inhibitors
heterocyclic
inhibitors
atr
Prior art date
Application number
HUE18831104A
Other languages
English (en)
Hungarian (hu)
Inventor
Francesco Maria Di
Philip Jones
Christopher Carroll
Jason Cross
Suyambu Kesava Ramaswamy
Michael Johnson
Sarah Lively
David Lapointe
Original Assignee
Univ Texas
Chempartner Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Chempartner Corp filed Critical Univ Texas
Publication of HUE066043T2 publication Critical patent/HUE066043T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE18831104A 2017-07-13 2018-07-13 A TR kináz beterociklusos inhibitorai HUE066043T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531951P 2017-07-13 2017-07-13

Publications (1)

Publication Number Publication Date
HUE066043T2 true HUE066043T2 (hu) 2024-07-28

Family

ID=64998660

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18831104A HUE066043T2 (hu) 2017-07-13 2018-07-13 A TR kináz beterociklusos inhibitorai

Country Status (24)

Country Link
US (3) US10392376B2 (enExample)
EP (1) EP3651768B1 (enExample)
JP (1) JP7159307B2 (enExample)
KR (1) KR102676822B1 (enExample)
CN (2) CN117466884A (enExample)
AU (1) AU2018301696B8 (enExample)
CA (1) CA3069693A1 (enExample)
DK (1) DK3651768T3 (enExample)
ES (1) ES2974334T3 (enExample)
FI (1) FI3651768T3 (enExample)
HR (1) HRP20240368T1 (enExample)
HU (1) HUE066043T2 (enExample)
IL (1) IL271930B (enExample)
LT (1) LT3651768T (enExample)
MX (1) MX2020000386A (enExample)
NZ (1) NZ761374A (enExample)
PH (1) PH12020500072A1 (enExample)
PL (1) PL3651768T3 (enExample)
PT (1) PT3651768T (enExample)
RS (1) RS65466B1 (enExample)
SI (1) SI3651768T1 (enExample)
SM (1) SMT202400106T1 (enExample)
WO (1) WO2019014618A1 (enExample)
ZA (1) ZA202000148B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
US10377591B2 (en) 2017-07-07 2019-08-13 Zebra Technologies Corporation Input handling for media processing devices
SMT202400106T1 (it) 2017-07-13 2024-05-14 Univ Texas Inibitori eterociclici della atr chinasi
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
JP7235338B2 (ja) * 2017-09-08 2023-03-08 ニューウェーブ・ファーマスーティカル・インコーポレイテッド Atr阻害剤としての置換ピロロピリジン
CN112218631B (zh) * 2018-03-16 2023-12-22 德州大学系统董事会 Atr激酶的杂环抑制剂
WO2020063751A1 (en) * 2018-09-27 2020-04-02 Fochon Pharmaceuticals, Ltd. Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
CN113906026A (zh) * 2019-06-06 2022-01-07 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
CN113121524B (zh) * 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
AU2021282122B2 (en) * 2020-05-29 2023-09-21 Wuxi Life Fountain Biotech Co., Ltd Fluoropyrrolopyridine compound and application thereof
CA3185491A1 (en) * 2020-07-03 2022-01-06 Antengene Discovery Limited Atr inhibitors and uses thereof
WO2022171034A1 (zh) * 2021-02-10 2022-08-18 江苏先声药业有限公司 作为hpk1抑制剂的双环类化合物及其应用
JP2024517906A (ja) * 2021-05-12 2024-04-23 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド スルホンイミドイル含有atr阻害剤化合物
CN117500789A (zh) * 2021-06-17 2024-02-02 杭州中美华东制药有限公司 一种吡啶硼酸酯的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265871A1 (en) * 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US20110034454A1 (en) * 2006-01-11 2011-02-10 Allan Paul Dishington Morpholino pyrimidine derivatives and their use in therapy
MX2009002046A (es) 2006-08-24 2009-03-06 Astrazeneca Ab Derivados de morfolino pirimidina utiles en el tratamiento de trastornos proliferativos.
CN101563340A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 用作pi3k和mtor抑制剂用于治疗增殖性疾病的2-苯并咪唑基-6-吗啉代-4-哌啶-4-基嘧啶衍生物
EP2146981A1 (en) 2007-04-12 2010-01-27 F. Hoffmann-Roche AG Pharmaceutical compounds
WO2008144500A2 (en) 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine, 1-oxide derivatives
ATE554075T1 (de) 2007-07-09 2012-05-15 Astrazeneca Ab Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate
EP2074118A2 (en) 2007-07-09 2009-07-01 AstraZeneca AB Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
AU2008273892A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
US20110015181A1 (en) 2008-03-06 2011-01-20 Makoto Ando Alkylaminopyridine derivative
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス, インコーポレイテッド Cdkモジュレーター
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
WO2010120996A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
JP2013032290A (ja) 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
WO2011106276A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
ES2535116T3 (es) 2010-03-04 2015-05-05 Cellzome Limited Derivados de urea sustituida con morfolino como inhibidores de mtor
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
BR112015012454B1 (pt) 2012-12-07 2022-07-05 Vertex Pharmaceuticals Incorporated Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
ES2768678T3 (es) 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 2-(嗎啉-4-基)-1,7-萘啶
BR112017007708B8 (pt) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Composto macrocíclico e composição farmacêutica
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
SMT202400106T1 (it) 2017-07-13 2024-05-14 Univ Texas Inibitori eterociclici della atr chinasi
EP3668839B1 (en) 2017-08-17 2023-04-12 Board of Regents, The University of Texas System Heterocyclic inhibitors of atr kinase
CN112218631B (zh) 2018-03-16 2023-12-22 德州大学系统董事会 Atr激酶的杂环抑制剂

Also Published As

Publication number Publication date
IL271930B (en) 2022-07-01
AU2018301696B8 (en) 2023-03-23
NZ761374A (en) 2025-10-31
US10392376B2 (en) 2019-08-27
KR102676822B1 (ko) 2024-06-19
CN117466884A (zh) 2024-01-30
PH12020500072A1 (en) 2020-11-09
US20210047311A1 (en) 2021-02-18
CN111867590A (zh) 2020-10-30
EP3651768A1 (en) 2020-05-20
IL271930A (en) 2020-02-27
ES2974334T3 (es) 2024-06-26
US11434233B2 (en) 2022-09-06
RS65466B1 (sr) 2024-05-31
LT3651768T (lt) 2024-04-25
CN111867590B (zh) 2023-11-17
AU2018301696A8 (en) 2023-03-23
EP3651768B1 (en) 2023-12-20
SMT202400106T1 (it) 2024-05-14
AU2018301696B2 (en) 2022-10-27
JP2020527174A (ja) 2020-09-03
JP7159307B2 (ja) 2022-10-24
DK3651768T3 (da) 2024-03-18
US20190016713A1 (en) 2019-01-17
FI3651768T3 (fi) 2024-03-14
EP3651768A4 (en) 2021-04-07
CA3069693A1 (en) 2019-01-17
KR20200028441A (ko) 2020-03-16
AU2018301696A1 (en) 2020-02-27
MX2020000386A (es) 2020-08-06
PL3651768T3 (pl) 2024-09-02
US10800769B2 (en) 2020-10-13
HRP20240368T1 (hr) 2024-08-30
US20200102296A1 (en) 2020-04-02
SI3651768T1 (sl) 2024-05-31
PT3651768T (pt) 2024-03-20
ZA202000148B (en) 2024-08-28
WO2019014618A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
IL271930A (en) Heterocyclic inhibitors of ATR kinase
EP3668839A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
IL279949A (en) Heterocyclic MCT4 inhibitors
IL255246A0 (en) Heterocyclic amides as kinase inhibitors
SG10202112496SA (en) Imidazole-containing inhibitors of alk2 kinase
EP3177295A4 (en) Uses of salt-inducible kinase (sik) inhibitors
SG11201608242XA (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3131900A4 (en) Heterocyclic kinase inhibitors
IL274207A (en) Aminoimidazopyridazines as kinase inhibitors
IL255750A (en) Heterocyclic compounds as kinase inhibitors
SG11202103142TA (en) Heterocyclic kinase inhibitors and uses thereof
IL266789A (en) Heterocyclic compounds as kinase inhibitors
EP3405477C0 (en) TRANSGLUTAMINASE INHIBITORS
EP3765008A4 (en) HETEROCYCLIC INHIBITORS OF THE ATR KINASE
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
ZA201808238B (en) Certain protein kinase inhibitors
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases